利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.018 秒)

    Salmonella and immunogenic composition containing the same as well as its use
    1.
    发明授权
    Salmonella and immunogenic composition containing the same as well as its use 有权

    公开(公告)号：US11236135B2

    公开(公告)日：2022-02-01

    申请号：US16607756

    申请日：2018-04-26

    申请人： HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

    发明人： Marc Erhardt ,  Sebastian Felgner ,  Dino Kocijancic ,  Siegfried Weiss

    IPC分类号： C07K14/255 ,  A61K35/74 ,  C12N1/36 ,  C12N15/52

    摘要： In a first aspect, the present invention relates to a mutated Salmonella strain comprising mutations in flagellin II genes, like the fliF gene, in particular, in addition the aroA gene, the IpxR gene, the pagP gene, the pagL gene, the ydiV gene and optionally the eptA gene and further optionally, the arnT gene. In a further aspect, immunogenic compositions comprising said Salmonella strain are provided optionally together with a pharmaceutically accepted carrier, diluent or effluent. Moreover, a method for producing outer membrane vesicles of Salmonella is provided, said method comprises the steps of cultivating the Salmonella strain according to the present invention and isolating the outer membrane vesicles accordingly. The present invention provides the bacteria or the outer membrane vesicles (OMVs) obtainable by the methods according to the present invention and its use as a transport moiety or as an immunogenic composition, like a vaccine or immunotherapy platform espedaily for therapeutic treatment of cancer of tissue or blood.

    PHARMACEUTICALS FOR INFLUENCING THE REACTION OF THE HUMAN IMMUNE SYSTEM
    2.
    发明申请
    PHARMACEUTICALS FOR INFLUENCING THE REACTION OF THE HUMAN IMMUNE SYSTEM 审中-公开
    用于影响人体免疫系统反应的药物

    公开(公告)号：US20110086367A1

    公开(公告)日：2011-04-14

    申请号：US12294987

    申请日：2007-04-03

    申请人： Michael Probst-Kepper ,  Frank Ocklenburg ,  Darius Moharregh-Khiabani ,  Robert Geffers

    发明人： Michael Probst-Kepper ,  Frank Ocklenburg ,  Darius Moharregh-Khiabani ,  Robert Geffers

    IPC分类号： C07K14/47 ,  C12N5/0783 ,  C12N15/86 ,  C12Q1/04 ,  G01N33/566

    CPC分类号： A61K35/17 ,  A61K38/179

    摘要： The present invention uses the potency and efficacy of human glycoprotein-A repetitions predominant protein (GARP), the gene of which is located on chromosome 11q13-11q14 in the reprogramming of antigen-specific effector T-helper cells, which are CD4+, towards a regulatory pheno type of pre-determined suppressor activity. In contrast to the known regulatory protein Foxp3 that only induces an incomplete regulatory phenotype without suppressor function, GARP is more efficient in inducing suppressor activity. Further, the use of GARP in the manufacture of pharmaceutical compositions is provided, allowing the production of antigen-specific Treg-cells, having a predetermined suppressor activity for a specific antigen.

    摘要翻译： 本发明使用人类糖蛋白-A重复主导蛋白（GARP）的功效和功效，其基因位于染色体11q13-11q14上，将抗原特异性效应子T辅助细胞重新编程为CD4 + 调节性类型的预定抑制活性。 与仅仅诱导不具有抑制功能的不完全调节表型的已知调节蛋白Foxp3相反，GARP在诱导抑制活性方面更有效。 此外，提供了在制备药物组合物中使用GARP，允许产生对具体抗原具有预定抑制活性的抗原特异性Treg细胞。